By Feroz Ali, The Hindu | July 28, 2017 India must counter Japan’s U.S.-style pressure at the RCEP talks and ensure affordable generic medicines Leaked texts are like leaked gases — you may never find the one responsible for it, … Continue reading
Granting a longer term for pharmaceutical patents will result in delays in the entry of generic versions and could adversely affect access to medicines By Feroz Ali, Live Mint | July 28, 2017 A proposal to further extend the … Continue reading
This gallery contains 11 photos.
These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation. My name is James Love. I work for Knowledge Ecology International, an … Continue reading
By Rohit Malpani, The Hindu | July 23, 2017 Hyderabad, well known as the hub of the Indian pharmaceuticals industry, ranks third globally in terms of its production volume, with a turnover of Rs. 18 billion a year. Most of … Continue reading
Published: The Huffington Post India By Leena Menghaney, Head—South Asia, Médecins Sans Frontières (MSF) Access Campaign. MÉDECINS SANS FRONTIÈRES (MSF) Officials from the 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) trade deal—which includes the ten ASEAN member states, … Continue reading
If accepted the trade deal measures will delay access to affordable medicines by restricting generic competition and maintaining monopoly pricing. Published: The Better India Officials from the sixteen countries negotiating the Regional Comprehensive Economic Partnership (RCEP) trade deal – which … Continue reading
Posted in Data Exclusivity, FTA, Generic competition, Generics, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized